Cantor Fitzgerald Trims Aimmune Therapeutics (NASDAQ:AIMT) Target Price to $32.00

Aimmune Therapeutics (NASDAQ:AIMT) had its price objective cut by Cantor Fitzgerald from $64.00 to $32.00 in a research note issued to investors on Monday, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

A number of other equities analysts also recently commented on AIMT. JMP Securities downgraded shares of Aimmune Therapeutics from an outperform rating to a market perform rating in a report on Wednesday, March 18th. ValuEngine upgraded shares of Aimmune Therapeutics from a hold rating to a buy rating in a report on Friday, February 28th. Roth Capital upped their price objective on shares of Aimmune Therapeutics from to in a report on Thursday, January 23rd. Credit Suisse Group cut their price objective on shares of Aimmune Therapeutics from to in a report on Monday, March 2nd. Finally, Stifel Nicolaus cut their price objective on shares of Aimmune Therapeutics from $34.00 to $32.00 and set a hold rating on the stock in a report on Monday, March 2nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $41.67.

Aimmune Therapeutics stock traded up $0.59 during trading hours on Monday, reaching $14.44. The stock had a trading volume of 1,509,103 shares, compared to its average volume of 1,884,287. The company has a market cap of $866.71 million, a price-to-earnings ratio of -3.64 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.14 and a quick ratio of 3.14. The business’s 50 day moving average price is $21.97 and its 200-day moving average price is $26.70. Aimmune Therapeutics has a 52 week low of $10.09 and a 52 week high of $37.00.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($1.06) EPS for the quarter, hitting the Zacks’ consensus estimate of ($1.06). During the same quarter in the prior year, the company earned ($0.95) earnings per share. On average, sell-side analysts forecast that Aimmune Therapeutics will post -3.94 EPS for the current fiscal year.

In related news, insider Daniel C. Md Adelman sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Andrew Oxtoby bought 3,000 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was purchased at an average price of $14.76 per share, for a total transaction of $44,280.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 132,665 shares of company stock worth $1,650,792. Corporate insiders own 13.75% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. FTB Advisors Inc. boosted its position in Aimmune Therapeutics by 67.3% in the fourth quarter. FTB Advisors Inc. now owns 1,039 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 418 shares during the last quarter. IFP Advisors Inc boosted its position in Aimmune Therapeutics by 23.9% in the fourth quarter. IFP Advisors Inc now owns 2,532 shares of the biotechnology company’s stock valued at $82,000 after buying an additional 488 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its position in Aimmune Therapeutics by 45.1% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,579 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 491 shares during the last quarter. Rhenman & Partners Asset Management AB boosted its position in Aimmune Therapeutics by 0.5% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 150,000 shares of the biotechnology company’s stock valued at $5,021,000 after buying an additional 799 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in Aimmune Therapeutics by 1.2% in the third quarter. California State Teachers Retirement System now owns 69,230 shares of the biotechnology company’s stock valued at $1,450,000 after buying an additional 827 shares during the last quarter. Hedge funds and other institutional investors own 74.69% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

See Also: Sell-Side Analysts

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.